Key Details
Price
$146.06Last Dividend
$0.32TTM Dividend Yield
0.87%PE Ratio
24.92Annual ROE
17.12%Beta
1.36Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Feb 6, 2025Recent annual earnings:
Feb 6, 2025Next ex-dividend date:
N/ARecent ex-dividend date:
Nov 29, 2024Next split:
N/ARecent split:
Nov 1, 2011Analyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Events
Dividend per share
Dividend yield
Other
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
In the fourth quarter, ITT's revenues rose by 12% compared to the same period last year. This growth was mainly due to an increase in industrial connectors in the Connect & Control Technologies segment and strong demand in the Industrial Process segment.
ITT Inc. (NYSE: ITT) will hold its Q4 2024 Results Conference Call on February 6, 2025, at 9:30 AM ET. The call will feature company representatives including Mark Macaluso, Luca Savi, and Emmanuel Caprais. Various analysts from firms like Goldman Sachs, Baird, and UBS will also participate in the discussion.
ITT (ITT) reported quarterly earnings of $1.50 per share, which is higher than the Zacks Consensus Estimate of $1.47 per share. This is an increase compared to last year's earnings of $1.34 per share.
STAMFORD, Conn.--(BUSINESS WIRE)--ITT Inc. (NYSE: ITT) has announced its financial results for the fourth quarter and the entire year that ended on December 31, 2024.
In addition to looking at analysts' estimates for ITT's revenue and earnings, it's important to assess predictions for some of its main metrics. This will help us understand how the company may have performed in the quarter that ended in December 2024.
In a study of patients who had biopsies at the start and after 96 weeks, 39% of those taking 50mg EFX showed at least one stage improvement in fibrosis without any worsening of MASH. This result indicates a 24% greater effect compared to the placebo group, which had a 15% improvement.
ITT has the potential to gain advantages from its strong performance in various areas. However, rising costs are still a worry.
ITT (ITT) has a strong track record of surprising with its earnings and currently has the right mix of factors that suggest it may exceed expectations in its upcoming quarterly report.
STAMFORD, Conn.--(BUSINESS WIRE)--ITT will announce its fourth quarter and full year results for 2024, along with its outlook for 2025, on Thursday, February 6.
ITT Inc. has consistently done better than its competitors, showing impressive revenue growth, profit margins, and free cash flow even in tough market situations. The company's smart mergers and acquisitions, along with increased market share in process control, connectors, and automotive sectors, set it up for future success. While short-term market recoveries are likely to increase revenue in 2025, high expectations and valuations could present some risks.
FAQ
- What is the ticker symbol for ITT?
- Does ITT pay dividends?
- What sector is ITT in?
- What industry is ITT in?
- What country is ITT based in?
- When did ITT go public?
- Is ITT in the S&P 500?
- Is ITT in the NASDAQ 100?
- Is ITT in the Dow Jones?
- When was ITT's last earnings report?
- When does ITT report earnings?
- Should I buy ITT stock now?